Sharp Daily
No Result
View All Result
Sunday, March 1, 2026
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
Sharp Daily
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
No Result
View All Result
Sharp Daily
No Result
View All Result
Home Healthcare

Rwanda recalls drug manufactured in Kenya

Brenda Murungi by Brenda Murungi
January 4, 2024
in Healthcare
Reading Time: 2 mins read

The Rwanda Food and Drugs Authority (RFDA) has initiated a voluntary recall of Fluconazole 200mg tablets produced by Universal Corporation (UCL) Ltd. in Kikuyu, Kenya. The recall encompasses all retail and facility levels, and it was officially announced on January 3, following a prior notification letter from the FDA to UCL regarding discoloration issues observed in the Fluconazole 200mg tablets.

RFDA disclosed that four bulk batches of pink Fluconazole 200mg tablets, which were imported into Rwanda, exhibited white discoloration shortly after their manufacture. The tablets, identified by four batch numbers and slated to expire on January 31 and August 31, 2025, were expected to maintain a pink color until the specified timelines but had transitioned to white prematurely.

In response, the RFDA has directed all importers, central medical stores, wholesalers, RMS branches, retailers, and both public and private health facilities to cease the distribution of the affected Fluconazole 200mg tablet batches. The statement issued by the RFDA emphasizes the necessity for these entities to return the recalled batches to their respective suppliers for proper management.

Fluconazole, utilized in the treatment of severe fungal or yeast infections such as vaginal candidiasis, oropharyngeal candidiasis (thrush), esophageal candidiasis, and other candida infections, demonstrated an unexpected discoloration issue in the identified batches. The RFDA, in the course of an investigation into the presence of the drug on the market, determined that the implicated tablet batches had indeed entered the Rwandan market.

RELATEDPOSTS

Rwanda suspends development cooperation with Belgium over political interference

February 19, 2025

Kagame wins re-election with 99.15% of the vote

July 16, 2024

Importers and suppliers of the affected medication are given a 10-day window, from the date of the official announcement, to report the imported quantities, distribution details, returns, and the remaining stock on hand to the RFDA.

While the Kenyan Ministry of Health has not provided information on the recall status of the drug from hospitals and chemists in Kenya, there are no reports of the pink tablets displaying discoloration in the Kenyan market as of now.

Previous Post

Ichung’wah to LSK: Are you saying there are no corrupt judges?

Next Post

James Orengo terms Ruto’s remarks as reckless and dangerous

Brenda Murungi

Brenda Murungi

Related Posts

Analysis

CBK 10th rate cut: A simple breakdown for everyday kenyans

February 13, 2026
Analysis

NSSF early pension access proposal

February 13, 2026
Analysis

Safaricom ziidi trader, bringing stock market investing to m-pesa

February 10, 2026
Analysis

Pension fund returns moderate in 2025 as falling interest rates weigh on performance

February 5, 2026
Healthcare

How international accreditation can strengthen healthcare training in Kenya

February 4, 2026
Analysis

NSE bond trades hit record Sh2.7 trillion on investor surge

January 23, 2026

LATEST STORIES

MPs raise alarm over domestic borrowing and risk to private sector credit

February 27, 2026

Court lifts freeze on Diageo’s EABL stake sale

February 27, 2026

How VAT and Excise Duty Impact Retirement Benefits in Kenya

February 27, 2026

Reducing dependency through better labour market policies

February 27, 2026

African Union and Africa’s Regional Blocs: Integration Ambition, External Influence, and the Trust Constraint

February 27, 2026

February 2026 inflation rate eases to 4.3 percent

February 27, 2026

Investor Rush Signals New Phase of Growth for Kenya’s E Mobility Secto

February 27, 2026

BAT investors set for higher returns following improved earnings

February 27, 2026
  • About Us
  • Meet The Team
  • Careers
  • Privacy Policy
  • Terms and Conditions
Email us: editor@thesharpdaily.com

Sharp Daily © 2024

No Result
View All Result
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team

Sharp Daily © 2024